Litigation Details for Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Docket		Date Filed	2012-06-26
Court	District Court, D. Delaware	Date Terminated	2013-11-01
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,148,356
Link to Docket	External link to docket

Details for Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-06-26				External link to document

Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC, 1:12-cv-00825: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Cumberland Pharmaceuticals sued Sagent Agila LLC in the U.S. District Court for the District of Delaware after Sagent filed an ANDA seeking approval for a generic version of Caldolor, Cumberland's injectable ibuprofen product. The case centered on U.S. Patent No. 6,727,286, which covered injectable ibuprofen compositions. The litigation ended through a settlement and stipulated dismissal rather than a judicial ruling on patent validity or infringement. Public filings indicate that Sagent's generic launch was restricted until the expiration of the asserted patent, subject to customary settlement exceptions.[1][2]

What was Cumberland Pharmaceuticals v. Sagent Agila about?

The dispute concerned Sagent's abbreviated new drug application for a generic injectable ibuprofen product corresponding to Caldolor.

Item	Details
Case	Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC
Civil action	No. 1:12-cv-00825
Court	U.S. District Court for the District of Delaware
Plaintiff	Cumberland Pharmaceuticals Inc.
Defendant	Sagent Agila LLC
Reference product	Caldolor injection
Active ingredient	Ibuprofen
Regulatory pathway	ANDA under the Hatch-Waxman Act
Asserted patent	U.S. Patent No. 6,727,286
Core issue	Whether Sagent's proposed generic injectable ibuprofen infringed the patent
Disposition	Settlement followed by stipulated dismissal
Trial outcome	No public adjudication on infringement, validity, or enforceability

Cumberland filed the action after receiving notice of Sagent's Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. The certification gives the NDA holder or patent owner 45 days to file suit. A timely lawsuit generally triggers a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[3]

What patent protected Caldolor in the Sagent litigation?

The principal asserted patent was U.S. Patent No. 6,727,286, titled generally as an injectable ibuprofen composition patent.

U.S. Patent No. 6,727,286

Patent attribute	Information
Patent number	6,727,286
Patent family subject	Injectable ibuprofen compositions
Listed product	Caldolor injection
Patent owner or asserted rights holder	Cumberland Pharmaceuticals and related rights holders
Filing and priority history	Based on an early-2000s application chain
Listed expiration	June 10, 2021
Patent type	Formulation and composition patent
Relevance to Sagent	Principal patent asserted against the ANDA

The patent protected the pharmaceutical composition and formulation technology used to provide ibuprofen in an injectable dosage form. The legal theory was therefore primarily a formulation-patent infringement case, rather than a dispute over a new chemical entity. Ibuprofen itself is a long-established active ingredient and was not protected by composition-of-matter exclusivity in this litigation.

The record does not indicate that Cumberland asserted a separate method-of-use patent against Sagent in this action. The case was directed to the injectable formulation described in the listed patent.

What was the litigation timeline?

The publicly reported chronology is as follows:

Date or period	Event
June 11, 2009	FDA approved Caldolor injection for Cumberland.[4]
2012	Sagent submitted an ANDA for a generic version of Caldolor and served a Paragraph IV notice.
2012	Cumberland filed Civil Action No. 1:12-cv-00825 in the District of Delaware.
2012-2013	The parties litigated the patent claims and related Hatch-Waxman issues.
2013	Cumberland and Sagent resolved the dispute through a settlement.
2013	The action was terminated through a stipulated dismissal.
June 10, 2021	The listed patent reached its stated expiration date.

Cumberland's public company filings describe the dispute as a patent action arising from Sagent's ANDA filing. Those filings also state that the parties entered into a settlement that permitted Sagent to market a generic product no earlier than the patent's expiration, subject to specified exceptions.[1][2]

Was there a Paragraph IV challenge to Caldolor?

Yes. The litigation was a Hatch-Waxman Paragraph IV case.

Sagent's ANDA certification placed the validity, enforceability, or infringement of the Caldolor patent in dispute before FDA approval of the generic. Cumberland's complaint preserved the statutory litigation pathway and triggered the regulatory consequences associated with a timely patent suit.

The public record does not show a final court determination that U.S. Patent No. 6,727,286 was invalid, unenforceable, or not infringed. The settlement eliminated the need for the court to decide those questions.

How did the Cumberland-Sagent settlement affect generic entry?

The settlement delayed Sagent's commercial launch until at least the stated expiration of U.S. Patent No. 6,727,286, subject to contractual exceptions.

The public disclosure did not provide the complete agreement or identify every possible early-entry condition. The disclosed commercial effect was clear: Sagent did not receive an immediate launch right, and Cumberland preserved the patent's market-exclusion period through the scheduled expiration date.

The settlement did not establish that the patent would have survived a validity or infringement challenge. It established a contractual resolution and ended the pending case.

What settlement terms were publicly disclosed?

Cumberland's securities filings disclosed the principal launch timing but not the complete economic terms. Publicly disclosed information does not establish:

• Any payment from Cumberland to Sagent.
• Any payment from Sagent to Cumberland.
• A royalty structure.
• A licensed manufacturing arrangement.
• An authorized generic arrangement.
• A covenant covering products beyond the challenged ANDA.
• The precise scope of any at-risk launch exception.

The absence of a public adjudication makes the settlement more important commercially than precedentially. The agreement controlled Sagent's launch position, but it did not create a binding judicial precedent on the patent's legal strength.

What was the FDA and Orange Book status of Caldolor?

Caldolor was an FDA-approved injectable ibuprofen product. The product was approved under NDA No. 022348 and was listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[4][5]

Regulatory item	Status
Product	Caldolor
Ingredient	Ibuprofen
Dosage form	Injection
NDA holder	Cumberland Pharmaceuticals
FDA approval	2009
Patent listing	U.S. Patent No. 6,727,286
Generic pathway	ANDA
Regulatory dispute	Paragraph IV patent challenge
Key patent expiration	June 10, 2021

Caldolor was not a biologic. The dispute therefore did not involve a biosimilar application under the Public Health Service Act. The relevant competitive pathway was an ANDA for a therapeutically equivalent generic injectable product.

Did the case involve biosimilar risk?

No. Biosimilar risk was not relevant to this action.

Caldolor is a small-molecule injectable drug containing ibuprofen. A competing manufacturer would use the ANDA pathway rather than the biosimilar pathway. The principal market risks were:

1. Paragraph IV patent litigation.
2. Formulation design-around activity.
3. FDA approval of a therapeutically equivalent injectable product.
4. Contractual launch restrictions created by settlement.
5. Manufacturing and supply capabilities for sterile injectable products.

The formulation patent could delay an ANDA entrant even though ibuprofen itself was off-patent.

How strong was Cumberland's patent estate?

The case established commercial leverage but did not establish adjudicated patent strength.

Factors supporting Cumberland's position

Cumberland had a listed patent covering the injectable product and obtained the benefit of a statutory Hatch-Waxman litigation stay after filing suit. The settlement also reportedly restricted Sagent's launch until patent expiration. Those facts indicate that the patent had sufficient commercial value to support a negotiated resolution.

The patent addressed an injectable formulation rather than the basic ibuprofen molecule. Formulation patents can create meaningful entry barriers when the formulation is difficult to design around or when the generic applicant must reproduce a narrow combination of ingredients and performance characteristics.

Factors limiting the legal conclusions

The court did not issue a claim-construction ruling, summary-judgment decision, trial judgment, or appellate opinion resolving the patent's validity or infringement. The settlement therefore does not prove that:

• The patent claims were valid.
• The patent was enforceable.
• Sagent's ANDA product infringed.
• The patent would have survived an obviousness challenge.
• The patent was difficult to design around.

The appropriate conclusion is that Cumberland achieved a negotiated delay of Sagent's entry, not that the patent received judicial confirmation.

What generic entry risks existed for Caldolor?

The main entry risk was a generic injectable ibuprofen product after the June 10, 2021 patent expiration date or under a settlement exception.

Formulation and manufacturing barriers

Sterile injectable products require manufacturing controls that can raise entry costs. Relevant barriers include:

• Aseptic processing.
• Container-closure integrity.
• Stability and shelf-life validation.
• Compatibility with intravenous administration.
• Control of particulate matter and impurities.
• Commercial-scale sterile manufacturing capacity.
• FDA inspection readiness.
• Hospital and distributor contracting.

These manufacturing requirements can delay commercial entry even after patent expiration. They do not, however, replace patent protection. A well-funded injectable manufacturer with existing sterile capacity can reduce those barriers.

Competitive products

Caldolor competed in the hospital injectable analgesic market, where alternatives included injectable opioids, ketorolac, acetaminophen injection, and other non-opioid or multimodal pain-management products. The relevant competitive question was not limited to an exact generic substitute. Hospital formularies could compare products based on efficacy, renal and gastrointestinal risk, opioid-sparing utility, acquisition cost, dosing convenience, and supply reliability.

How did Caldolor's patent protection compare with ordinary generic-drug protection?

Caldolor illustrates the difference between molecule-level and formulation-level exclusivity.

Protection type	Caldolor status
New chemical entity exclusivity	Not applicable to ibuprofen
Composition-of-matter patent on ibuprofen	Not available
Injectable formulation patent	U.S. Patent No. 6,727,286
Method-of-use patent in this case	Not publicly identified as the asserted basis
ANDA litigation	Yes
Biosimilar litigation	No
Patent-based delay	Yes, through settlement
Final validity ruling	No

The commercial value of Cumberland's estate came from the dosage-form and formulation patent. Such patents can extend practical exclusivity for an approved product after the active ingredient has become generic, but their value depends on claim scope, prior art, design-around options, and the technical requirements of the ANDA product.

What was the revenue exposure from Sagent's challenge?

Cumberland's public filings identify Caldolor as a commercial product but do not establish a case-specific revenue amount attributable to Sagent's proposed entry. The economic exposure included:

• Loss of hospital sales to an ANDA-approved injectable substitute.
• Price erosion from generic competition.
• Reduced gross margin.
• Potential loss of formulary position.
• Distributor and group-purchasing pressure.
• Reduced value of the Caldolor franchise before patent expiry.

The settlement protected the product from Sagent's immediate entry but did not prevent competition from other manufacturers after patent expiry or from non-infringing products before that date.

What is the current litigation status?

The case is closed. It ended through settlement and stipulated dismissal rather than trial or appellate review.

There is no reported final judgment in the action determining that Sagent infringed U.S. Patent No. 6,727,286, nor a reported judgment invalidating the patent. The case should therefore be classified as a settled Hatch-Waxman formulation-patent dispute with no substantive merits precedent.

What does the case mean for generic launch analysis?

The likely launch framework was:

Scenario	Commercial effect
Sagent complied with the settlement	Launch delayed until at least June 10, 2021
Sagent obtained an authorized early-entry right	Launch possible on the contractually permitted date
Patent invalidated in later litigation	Earlier entry could become possible, subject to FDA status
Non-infringing design-around approved	Entry could occur without waiting for patent expiration
Patent expiration without competing approval	No automatic commercial launch; FDA approval and manufacturing remained necessary
Post-expiration ANDA competition	Price and market-share pressure likely

The principal legal risk was resolved contractually rather than by judgment. The principal regulatory risk remained whether Sagent's ANDA would receive FDA approval and whether its product could meet sterile injectable manufacturing requirements.

Key Takeaways

• Cumberland sued Sagent Agila over an ANDA for generic Caldolor injectable ibuprofen.
• The case was filed in the District of Delaware as No. 1:12-cv-00825.
• U.S. Patent No. 6,727,286 was the principal asserted patent.
• The patent covered injectable ibuprofen formulation technology, not the ibuprofen molecule itself.
• Sagent's Paragraph IV certification triggered the Hatch-Waxman litigation.
• The parties settled and the case was dismissed without a trial.
• Public disclosures indicate that Sagent's launch was delayed until at least the patent's June 10, 2021 expiration date, subject to settlement exceptions.
• No public merits ruling established infringement, validity, or enforceability.
• Biosimilar analysis does not apply because Caldolor is a small-molecule injectable drug.
• The principal residual barriers were FDA approval, sterile manufacturing, hospital contracting, and competition from other analgesic products.

FAQs

Did Cumberland win the patent case against Sagent?

No judicial win was recorded. Cumberland obtained a settlement that restricted Sagent's launch, but the court did not issue a final decision on patent infringement or validity.

What drug was Sagent trying to copy?

Sagent sought approval for a generic injectable ibuprofen product corresponding to Caldolor, Cumberland's FDA-approved intravenous ibuprofen product.

Was U.S. Patent No. 6,727,286 a composition-of-matter patent?

No. It was directed to injectable ibuprofen compositions and formulation technology. It did not provide new-chemical-entity protection for ibuprofen.

Could Sagent launch before June 10, 2021?

Only if permitted under a settlement exception, if the patent ceased to block approval, or if Sagent obtained an approved non-infringing product that was outside the settlement's restrictions. The complete settlement terms were not publicly disclosed.

Does the Cumberland-Sagent case create precedent for later Caldolor litigation?

No substantive precedent. Because the action ended in settlement and dismissal, it does not establish a binding ruling on the scope, validity, or enforceability of the Caldolor patent.

References

1. Cumberland Pharmaceuticals Inc. (2013). Annual report on Form 10-K for the fiscal year ended December 31, 2012. U.S. Securities and Exchange Commission.

2. Cumberland Pharmaceuticals Inc. (2014). Annual report on Form 10-K for the fiscal year ended December 31, 2013. U.S. Securities and Exchange Commission.

3. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

4. U.S. Food and Drug Administration. (2009). Caldolor approval package, NDA No. 022348. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2021). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

6. U.S. District Court for the District of Delaware. (2012-2013). Cumberland Pharmaceuticals Inc. v. Sagent Agila LLC, No. 1:12-cv-00825. Docket record.